Anti-Human EGFR x MET (Amivantamab) - 1 mg

All|Recombinant Antibodies>Biosimilar Recombinant Antibodies|Primary Monoclonal Antibodies

2 - 8°C Wet Ice

Anti-Human EGFR x MET bispecific antibodies have shown promising results in cancertherapy. These antibodies target both the epidermal growth factor receptor (EGFR) and theMET receptor, which are crucial in cancer progression and resistance mechanisms. Studieshave demonstrated that bispecific antibodies can inhibit proliferation, migration, and invasivegrowth of tumor cells more effectively than single-agent treatments. Additionally, theseantibodies have been found to enhance tumor growth inhibition and downregulate bothEGFR and MET receptors, highlighting their potential in combating therapeutic resistance inpatients with EGFR mutations. The combination of EGFR and MET inhibition throughbispecific antibodies presents a valuable strategy for overcoming resistance mechanismsand improving treatment outcomes in cancer patients1-3. Amivantamab (JNJ-611) is a human bispecific monoclonal antibody that targets both theEGFR and the hepatocyte growth factor receptor (HGFR/cMet). This bispecific antibody isengineered to simultaneously bind to wild-type and mutant forms of EGFR and MET, therebyblocking their phosphorylation and subsequent signaling pathways essential for cancer cellproliferation. Preclinical studies demonstrated the superior efficacy of Amivantamab inmodels with EGFR exon 20 insertions compared to other therapies like cetuximab orpoziotinib. In clinical settings, Amivantamab has shown promise in treating patients withNSCLC, particularly those with EGFR exon 20 insertion mutations who have progressedafter platinum-based chemotherapy1, 3.

≥ 5.0 mg/ml

EGFR and MET are widely expressed in various epithelial tissues, including lung, skin, and digestive tract linings. In cancer cells, these receptors can beoverexpressed or mutated, driving tumorigenesis.